Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Thyroid cancer: trends in incidence, mortality and clinical-pathological patterns in Zhejiang Province, Southeast China

Authors: Lingbin Du, Youqing Wang, Xiaohui Sun, Huizhang Li, Xinwei Geng, Minghua Ge, Yimin Zhu

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Thyroid cancer is the most common malignant disease of the endocrine system. Previous studies indicate a rapid increase in the incidence of thyroid cancer in recent decades, and this increase has aroused the great public concern. The aim of this study was to analyze the trends in incidence, mortality and clinical-pathological patterns of thyroid cancer in Zhejiang province.

Methods

Population-based incidence and mortality rates of thyroid cancer were collected from eight cancer registries in Zhejiang from 2000 to 2012. The incidence and mortality rates were age-standardized to Segi’s world population. A Joinpoint model was used to examine secular trends in age-adjusted thyroid cancer rates with the Joinpoint Regression Program Version 4.0.0. Thyroid cancer patients were recruited from Zhejiang Cancer Hospital from 1972 to 2014. Patient demographics, tumor histology and tumor size were compared among the different periods of 1972–1985, 1986–1999 and 2000–2014.

Results

The age-standardized incidence rate of thyroid cancer in Zhejiang cancer registries was 2.75/105 in 2000, and increased to 19.42/105 in 2012. Additionally, we observed significantly increasing incidence rates with the Annual Percent Change (APC) of 22.86% (95%CI, 19.2%–26.7%). The age-standardized mortality of thyroid cancer in Zhejiang cancer registries was 0.23/105 in 2000 and 0.25/105 in 2012. No significant change in mortality rate was found. We observed a rapid increase in the proportions of papillary thyroid carcinoma (PTC) in 12,508 patients with thyroid carcinoma identified in the Zhejiang Cancer Hospital from 1972 to 2014 while the proportions of poorly differentiated thyroid cancer (PDTC), medullary thyroid carcinoma (MTC) and follicular thyroid carcinoma (FTC) decreased over the decades. In the PTC cases, the proportion of patients with maximum tumor diameter (MTD) < 1 cm dramatically and significantly increased from 0 in 1972–1985 to 32.1% in 2000–2014.

Conclusions

A rapid increase in incidence and a stable trend in mortality of thyroid cancer were found in the distribution of thyroid cancer. Most of the increased incidence was PTC, especially the papillary thyroid microcarcinoma (PTMC) with MTD < 1 cm. This increase in incidence might be due to increased diagnosis with advanced technology.
Literature
1.
Curado M, Edwards B, Shin H, et al. editors. Cancer incidence in five continents, Volume IX. IARC Sci Publ. 2008(160):1-837.
2.
Kilfoy BA, Devesa SS, Ward MH, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1092–100.CrossRefPubMedPubMedCentral
3.
Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20(5):525–31.CrossRefPubMed
4.
Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomark Prev. 2009;18(3):784–91.CrossRef
5.
Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer. 2001;85(9):1335–9.CrossRefPubMedPubMedCentral
6.
Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MWJ. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol. 2005;62(2):156–62.CrossRef
7.
La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. International journal of cancer. Int J Cancer. 2015;136(9):2187–95.CrossRefPubMed
8.
Franceschi S, Vaccarella S. Thyroid cancer: an epidemic of disease or an epidemic of diagnosis? International journal of cancer. Int J Cancer. 2015;136(11):2738–9.CrossRefPubMed
9.
Busco S, Giorgi Rossi P, Sperduti I, Pezzotti P, Buzzoni C, Pannozzo F. Increased incidence of thyroid cancer in Latina, Italy: a possible role of detection of subclinical disease. Cancer Epidemiol. 2013;37(3):262–9.CrossRefPubMed
10.
Colonna M, Uhry Z, Guizard A, et al. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol. 2015;39(4):511–8.CrossRefPubMed
11.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7.CrossRefPubMed
12.
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317–22.CrossRefPubMed
13.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801–7.CrossRefPubMed
14.
Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”--screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–7.CrossRefPubMed
15.
Du LB, Li HZ, Wang XH, et al. Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009. Asian Pac J Cancer Prev. 2014;15(14):5839–43.CrossRefPubMed
16.
Xie WC, Chan MH, Mak KC, Chan WT, He M. Trends in the incidence of 15 common cancers in Hong Kong, 1983-2008. Asian Pac J Cancer Prev. 2012;13(8):3911–6.CrossRefPubMed
17.
Xie SH, Chen J, Zhang B, et al. Time trends and age-period-cohort analyses on incidence rates of thyroid cancer in shanghai and Hong Kong. BMC Cancer. 2014;14:975.CrossRefPubMedPubMedCentral
18.
Ceresini G, Corcione L, Michiara M, et al. Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of northern Italy, 1998 to 2009. Cancer. 2012;118(22):5473–80.CrossRefPubMed
19.
Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control. 2009;20(1):75–86.CrossRefPubMed
20.
Schonfeld SJ, Lee C. Berrington de Gonzalez a. Medical exposure to radiation and thyroid cancer. Clin Oncol. 2011;23(4):244–50.CrossRef
21.
Cho YA, Kim J. Dietary factors affecting thyroid cancer risk: a meta-analysis. Nutr Cancer. 2015;67(5):811–7.CrossRefPubMed
22.
Vaccarella S, Dal ML, Laversanne M, et al. The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries. Thyroid. 2015;25(10):1127–36.CrossRefPubMed
23.
O'Grady TJ, Gates MA, Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011. International journal of cancer. Int J Cancer. 2015;137(11):2664–73.CrossRefPubMed
24.
Brito JP, Al Nofal A, Montori VM, Hay ID, Morris JC. The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in Olmsted County, Minnesota during 1935 through 2012. Thyroid. 2015;25(9):999–1007.CrossRefPubMedPubMedCentral
25.
Vucemilo L, Znaor T, Kulis T, Sekerija M, Znaor A. Thyroid cancer incidence and mortality trends in Croatia 1988-2010. Acta Clin Croat. 2015;54(1):30–7.PubMed
26.
Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47(2):127–41.CrossRefPubMedPubMedCentral
27.
28.
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.CrossRefPubMed
29.
Lawal O, Agbakwuru A, Olayinka OS, Adelusola K. Thyroid malignancy in endemic nodular goitres: prevalence, pattern and treatment. Eur J Surg Oncol. 2001;27(2):157–61.CrossRefPubMed
30.
Dijkstra B, Prichard RS, Lee A, et al. Changing patterns of thyroid carcinoma. Ir J Med Sci. 2007;176(2):87–90.CrossRefPubMed
31.
Yang L, Zheng R, Wang N, Zhang S, Chen W. Analysis of incidence and mortality of thyroid cancer in China, 2010. Zhonghua Yu Fang Yi Xue Za Zhi. 2014;48(8):663–8.PubMed
32.
Song K, Du L, Li H, Wang X, Mao W, Yu C. Incidence and mortality of thyroid cancer in six cancer registries of Zhejiang province, 2000-2009. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49(6):493–6.PubMed
33.
Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56(3):531–8.CrossRefPubMed
34.
Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71(12):4022–9.CrossRefPubMed
35.
Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357–61.CrossRefPubMedPubMedCentral
36.
Grodski S, Brown T, Sidhu S, et al. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008;144(6):1038–43. discussion 1043CrossRefPubMed
37.
Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16(1):47–53.CrossRefPubMed
38.
Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid. 2013;23(1):103–10.CrossRefPubMedPubMedCentral
39.
Mettler FA, Sinclair WK, Anspaugh L, et al. The 1986 and 1988 UNSCEAR (United Nations scientific committee on the effects of atomic radiation) reports: findings and implications. Health Phys. 1990;58(3):241–50.CrossRefPubMed
40.
Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013;346(10):f2360.CrossRefPubMedPubMedCentral
Metadata
Title
Thyroid cancer: trends in incidence, mortality and clinical-pathological patterns in Zhejiang Province, Southeast China
Authors
Lingbin Du
Youqing Wang
Xiaohui Sun
Huizhang Li
Xinwei Geng
Minghua Ge
Yimin Zhu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4081-7

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer

Research article

ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL

Research article

The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model

Research article

GPNMB methylation: a new marker of potentially carcinogenic colon lesions

Research article

Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan

Research article

AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits